Moberg Pharma (MOB) Q2 2026 earnings summary

Executive summary

• Achieved a 76% mycological cure rate in two Phase 3 studies with over 800 patients, demonstrating unprecedented efficacy for a topical nail fungus treatment.

• TerclaraⓇ (MOB-015) maintained rapid market leadership in Sweden and Norway, with strong pharmacy sales shares in both value and units.

• Commercial partnerships and licensing agreements secured across Europe, Canada, APAC, China, Scandinavia, and Israel, expanding collaboration with Karo Healthcare.

• Approved in 14 markets, with launches planned in additional countries and first deliveries outside Nordics expected around year-end.

• Strengthened management team and board to support international expansion and upcoming product launches.

Segment performance

• In Sweden, TerclaraⓇ holds a 44% value share and 38% unit share in Q2 2026; Norway saw a 42% value share and 37% unit share.

• Market leadership established in both Sweden and Norway, with ongoing launches planned in other European and international markets.

Significant events and developments

• Awarded 'Launch of the Year 2024' by major Swedish pharmacy chains for revitalizing the category and driving market share.

• Nominated for 'Launch of the Year 2025' in Norway by leading pharmacy chains.

• Expanded licensing agreements with Karo Healthcare to cover APAC and China.

• First European countries approved transition to Karo Healthcare trademarks, enabling launch preparations.

• New board members and Chairman appointed at AGM; long-term incentive program implemented.